Immunotherapy and allogeneic stem cells transplantation

被引：0
|
作者：
de Fontbrune, Flore Sicre [1 ]
Cavalieri, Doriane [2 ]
Leclerc, Mathieu [3 ]
Beckerich, Florence [3 ]
Maury, Sebastien [3 ]
de latour, Regis Peffault [1 ]
N-Guyen, Stephanie [4 ]
Bay, Jacques-Olivier [2 ]
机构：
[1] GH Henri Mondor, Hematol Clin & Transplantat, Creteil, France
[2] CHU Clermont Ferrand, Serv Theapie Cellulaire & Hematol Clin Adulte, Site Estaing 1,Pl Lucie Aubrac, F-63000 Clermont Ferrand, France
[3] Hop St Louis, Serv Hematol Greffe Moelle, 1 Ave Claude Vellefaux, F-75475 Paris 10, France
[4] Univ Paris 06, Univ Sorbonne, AP HP,CNRS ERL8255,Serv Hematol Clin, Ctr Immunol & Malad Infect CIMI Paris,INSERM U113, Paris, France
来源：
BULLETIN DU CANCER | 2016年 / 103卷
关键词：
HLA typing; Allogeneic transplantation; Immunotherapy; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; DONOR LYMPHOCYTE INFUSIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; CORD BLOOD TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; MINOR HISTOCOMPATIBILITY ANTIGENS; DE-THERAPIE-CELLULAIRE; REDUCED-INTENSITY; T-CELLS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Allogeneic stem cell transplantations represent perfect example of immunotherapy. Its positive aspects are due to the graft versus tumor effect. Unfortunately, this therapeutic advantage is usually associated with graft versus host effects. While the mechanism of these two graft reactions remain unclear, this is possible to modulate these immunologic effects. The type of conditioning regimen, the source of donor and the use of donor cells after the transplantation may influence the toxicity and the tumor response, leading to a better optimization of the procedure. This paper is presenting all the parameters which may contribute to improve allogeneic stem cell transplantations.
引用
收藏
页码：S164 / S174
页数：11
相关论文
共 50 条
  • [21] Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation
    Tamari, Roni
    Oran, Betul
    Hilden, Patrick
    Maloy, Molly
    Kongtim, Piyanuch
    Papadopoulos, Esperanza B.
    Rondon, Gabriela
    Jakubowski, Ann A.
    Andersson, Borje S.
    Devlin, Sean M.
    Ahmed, Sairah
    Popat, Uday R.
    Ponce, Doris
    Chen, Julianne
    Sauter, Craig
    Young, James W.
    de Lima, Marcos
    Perales, Miguel-Angel
    O'Reilly, Richard J.
    Giralt, Sergio A.
    Champlin, Richard E.
    Castro-Malaspina, Hugo
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (05) : 1079 - 1087
  • [22] Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation
    Bleakley, Marie
    Turtle, Cameron J.
    Riddell, Stanley R.
    EXPERT REVIEW OF HEMATOLOGY, 2012, 5 (04) : 409 - 425
  • [23] Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?
    Pichler, Herbert
    Fritsch, Gerhard
    Koenig, Margit
    Daxberger, Helga
    Glogova, Evgenia
    Poetschger, Ulrike
    Breuer, Sabine
    Lawitschka, Anita
    Gueclue, Ece D.
    Karlhuber, Susanne
    Holter, Wolfgang
    Haas, Oskar A.
    Lion, Thomas
    Matthes-Martin, Susanne
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (06) : 905 - 917
  • [24] Allogeneic stem cell transplantation in multiple myeloma: is there still a place?
    Liberatore, Carmine
    Fioritoni, Francesca
    Di Ianni, Mauro
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [25] Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma
    Bruno, Benedetto
    Lia, Giuseppe
    Bonifazi, Francesca
    Giaccone, Luisa
    HEMATO, 2021, 2 (01): : 89 - 102
  • [26] High-dose etoposide in allogeneic stem cell transplantation
    Bruserud, Oystein
    Reikvam, Hakon
    Kittang, Astrid Olsnes
    Ahmed, Aymen Bushra
    Tvedt, Tor Henrik Anderson
    Sjo, Malvin
    Hatfield, Kimberley Joanne
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (06) : 765 - 782
  • [27] Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution
    Brissot, E.
    Rialland, F.
    Cahu, X.
    Strullu, M.
    Corradini, N.
    Thomas, C.
    Blin, N.
    Rialland, X.
    Thebaud, E.
    Chevallier, P.
    Moreau, P.
    Milpied, N.
    Harousseau, J. L.
    Mechinaud, F.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2016, 51 (02) : 267 - 272
  • [28] Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation
    Wong, Eric
    Davis, Joanne E.
    Grigg, Andrew
    Szer, Jeff
    Ritchie, David
    BONE MARROW TRANSPLANTATION, 2019, 54 (02) : 175 - 189
  • [29] Who is fit for allogeneic transplantation?
    Deeg, H. Joachim
    Sandmaier, Brenda M.
    BLOOD, 2010, 116 (23) : 4762 - 4770
  • [30] Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation
    Mo, Xiao-Dong
    Qin, Ya-Zhen
    Zhang, Xiao-Hui
    Xu, Lan-Ping
    Wang, Yu
    Yan, Chen-Hua
    Chen, Huan
    Chen, Yu-Hong
    Han, Wei
    Wang, Feng-Rong
    Wang, Jing-Zhi
    Liu, Kai-Yan
    Huang, Xiao-Jun
    ANNALS OF HEMATOLOGY, 2016, 95 (08) : 1233 - 1240
12345